1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Tris Exploring All Options For Cebranopadol After Second Positive Phase III

 
• By Jessica Merrill

A Phase III trial evaluating cebranopadol for acute pain following bunionectomy surgery was positive, positioning the drug for regulatory filing later this year.

(Shutterstock)
Key Takeaways
  • Cebranopadol showed stronger analgesic effect than oxycodone in a Phase III trial in patients following bunionectomy surgery.
  • The positive data represent the second successful readout for cebranopadol, which is positioned for a regulatory filing this year.
  • Tris is a private company but is positioned to commercialize cebranopadol on its own, if it does not find a partner, CEO Ketan Mehta said in an interview.

Tris Pharma is considering all options when it comes to commercializing the novel drug cebranopadol for acute pain after a second Phase III trial read out positively. The company is...

“This is such an important opportunity to address a huge problem, and we’ll remain very open-minded about how we go best about commercializing it,” CEO Ketan Mehta said in an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from Business

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.